Biologic Therapy for Psoriasis Clinical Practice Guidelines
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The British Association of Dermatologists have released an updated clinical guideline on Biologic Therapy for Psoriasis 2020. The guideline is published in British Journal of Dermatology.

The purpose of this guideline is to provide evidence-based recommendations on the use of biologic therapies targeting tumour necrosis factor (TNF) (adalimumab, etanercept, certolizumab pegol, infliximab), interleukin (IL)-12/23p40 (ustekinumab), IL-17A (ixekizumab, secukinumab), IL-17RA (brodalumab) and IL-23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.

These evidence and consensus-based (good practice point, GPP) recommendations should be considered in the context of the individual needs of the patient, with cross-reference to the relevant drug's SPC and the Implementation Toolkit.

About the society: The British Association of Dermatologists (BAD) is a charity whose charitable objects are the practice, teaching, training and research of Dermatology. It works with the Department of Health, patient bodies and commissioners across the UK, advising on best practice and the provision of Dermatology services across all service settings. It is funded by the activities of its Members.

Note: This list is a brief compilation of some of the key recommendations included in the Guideline and is not exhaustive and does not constitute medical advice. Kindly refer to the original document below.

Source: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.19039
Like
Comment
Share